Latest News

Photocure will present its second quarter and first half year report on Wednesday 7 August 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

Oslo, Norway, August 1, 2019 - Photocure ASA (OSE: PHO) management is conducting investor meetings in New York (US) on August 1, 2019, in connection with the European Biotech Investor Day, organized by Solebury Trout and sponsored by Goodwin LLC, Deutsche Bank, H.C. Wainwright and Nasdaq.

A new publication reviews this shift in the treatment paradigm for bladder cancer patients, discussing clinical benefits and cost management of the procedure.

Oslo, Norway July 1, 2019: Photocure ASA (Photocure, PHO: OSE), today announced that it has entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira® for the treatment of HPV induced cervical precancerous lesions. Under the agreement, Photocure will receive signing fees, development- and approval milestones, in addition to sales royalties.

Oslo, Norway, 19 June 2019: Photocure ASA (OSE: PHO), held an extraordinary general meeting on 19 June 2019 at 16:00 hours (CET).

Oslo, Norway, 18 June 2019 Photocure ASA (OSE: PHO), announces today that it has repurchased 1,694 own shares at NOK 0 per share in relation to the long-term incentive programme described in the stock exchange release on 7 May 2018.

Plenary and poster sessions focusing on the patient perspective and the important role of urology nurses in supporting the patient and alleviating anxiety 

Oslo, 28 Mai 2019: Photocure ASA (OSE: PHO), calls for an extraordinary general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 19 June 2019 at 16:00 hours (CET).

Data from a prospective intervention study in non-muscle-invasive bladder cancer (NMIBC) patients show that a systematic, guideline-based approach to the first TURBT improve patient outcomes.

Oslo, Norway, 14 May 2019: Photocure ASA (OSE:PHO), today reported a revenue growth of 52% in local currency for the U.S. market in the first quarter of 2019, contributing to Hexvix/Cysview revenues of NOK 51.2 million (Q1 2018: NOK 40.7) and a recurring EBITDA of NOK -1.5 million (NOK -4.0 million). The company continues to receive strong endorsement for the use of Blue Light Cystoscopy (BLC) with Cysview and reiterates the significant revenue growth and profit opportunities in the U.S. market.

Oslo, Norway, 9 May 2019: Photocure ASA (OSE: PHO), held its annual general meeting on 9 May 2019 at 17:00 hours (CET).

Photocure will present its first quarter report on Tuesday 14 May 2019 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

OSLO, Norway, May 6, 2019 - Photocure ASA (OSE: PHO) today announced key data presented at the 2019 American Urological Association (AUA) Annual Meeting in Chicago.  Session presentations and a poster presentation discussed Blue Light Cystoscopy (BLC™) with Cysview.

Oslo, Norway, 30 April 2019: Photocure ASA announced today that a study published in World Journal of Urology, shows that patients who undergo bladder tumor resection with Blue Light Cystoscopy (BLC™) with Hexvix® exhibit improved outcomes even if they progress to disease stages which require radical cystectomy.

Oslo, Norway April 25th, 2019, Photocure ASA (Photocure, PHO: OSE), today announced an Expert Consensus on the optimal use of Blue Light Cystoscopy (BLC™) with Cysview® in Nature Reviews Urology.

Oslo, 17 April 2019: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Hoffsveien 4, 1st floor, 0275 Oslo, Norway on 9 May 2019 at 17:00 hours (CET).

Oslo, 17 April 2019: Photocure ASA (OSE: PHO), has published the annual accounts and annual report for the financial year 2018.